VIP (Vasoactive Intestinal Peptide): Research Overview

• VIP is a 28-amino-acid neuropeptide that signals through VPAC1 and VPAC2 receptors.
• Research links VIP to immune balance, anti-inflammatory signaling, gut and lung function, and circadian timing.
• VIP signaling can also support tumor immune escape in some settings, which is why receptor antagonists are being studied in leukemia models.
• Human and animal studies do not point in one direction only. VIP can be helpful in one context and harmful in another.

What VIP Is

Vasoactive Intestinal Peptide, or VIP, is a 28-amino-acid neuropeptide. It is made in the nervous system and in other tissues. Research describes it as a pleiotropic signaling molecule, which means it can affect more than one body system at the same time. It acts through two main receptors, VPAC1 and VPAC2.

Older and newer papers both describe VIP as a strong anti-inflammatory signal. In immune cells, VIP has been shown to reduce pro-inflammatory activity and support more regulated immune responses. A 2009 review in Clinical & Experimental Immunology described VIP as an endogenous anti-inflammatory neuropeptide with therapeutic potential in inflammatory disease. A separate review in Emerging Roles of Vasoactive Intestinal Peptide described VIP as helping maintain immune tolerance in two ways: by shifting the balance away from pro-inflammatory factors and by promoting regulatory T cells.

That is the core theme in VIP research: it is not just a gut peptide. It is a broad signaling molecule with effects across immunity, the lungs, the brain, and possibly tumor biology.

How VIP Acts In The Body

Immune signaling

Several sources describe VIP as a regulator of immune balance. In immune cells, VIP signaling through VPAC1 and VPAC2 is linked with lower NF-kB activity and lower production of cytokines such as IL-6, TNF-alpha, and IL-12. Some sources also describe support for IL-10 and TGF-beta1 signaling, along with more regulatory T-cell activity.

The key idea is not simple immune suppression. The research points to immune modulation. VIP can calm an overactive inflammatory response while helping maintain tolerance. That makes it interesting in autoimmune and inflammatory settings, but it also creates a caution: the same pathway may reduce useful immune attack in cancer.

Lung and airway effects

VIP is described in clinical and lab materials as a bronchodilator and pulmonary vasodilator. One lab reference notes that VIP is the primary endogenous bronchodilator in the lungs and that VIP-deficient states are associated with pulmonary arterial hypertension and airway hyperresponsiveness. This is one reason VIP has been discussed in lung and airway research.

Circadian rhythm and timing

Some patient-facing material says VIP is typically administered in the morning or early afternoon to match its natural role in circadian rhythms, energy, and cellular regulation. That timing advice appears in a product information document, not in a large human trial. Still, it reflects an active research interest in VIP as a chronobiotic signal, especially in the brain’s clock-related pathways.

Gut and neuro-immune signaling

VIP has also been framed as part of the neuro-immune-gut axis. This view shows up in integrative medicine writing and in earlier scientific reviews. The source material describes VIP as involved in gut integrity, autonomic signaling, and communication between tissues. That framing fits the broader receptor distribution: VIP receptors are found in the hypothalamus, lung, small intestine, immune cells, pituitary gland, and vascular smooth muscle.

What The Research Suggests In Disease

Inflammation and autoimmunity

Older review work argues that VIP may help maintain immune tolerance. In that model, VIP can reduce excess inflammation and promote regulatory T cells that keep autoreactive effector cells in check. The sources do not claim this is proven treatment for autoimmune disease. They do show why VIP has attracted attention in inflammatory biology.

One thyroid study adds another layer. A 2020 paper on autoimmune thyroid disease reported that the VIP axis was dysfunctional in patients with autoimmune thyroid conditions, including Hashimoto’s thyroiditis and Graves’ disease. That does not prove causation, but it supports the idea that VIP signaling may be altered in autoimmune illness.

Leukemia and cancer research

The strongest experimental data in the bundle comes from leukemia models. A 2017 paper reported that blocking VIP signaling with the antagonist VIPhyb improved T-cell-dependent anti-leukemia responses in mouse models of acute myeloid leukemia and T lymphoblastic leukemia. In those models, subcutaneous VIPhyb reduced tumor burden and improved survival, with reported survival of 30-50% versus 0-20% in vehicle-treated controls.

A newer 2026 paper went further. It screened variants of a VIP antagonist and found peptides with better predicted receptor binding and better anti-leukemia activity. In that study, ANT308 and ANT195 stood out. The paper reports that ANT308 decreased CREB phosphorylation, a downstream VIP receptor signal, and increased granzyme B and perforin expression in CD8+ T cells from AML patients. The authors suggest these antagonists as candidates for further development as immunotherapies in relapsed AML.

This is an important point for VIP readers: VIP signaling is not universally “good.” In some cancers, especially in these leukemia models, VIP appears to contribute to immune suppression. Blocking it may help the immune system attack better.

Metabolism and appetite

The source list also points to a review on appetite, body composition, and metabolic hormones. That tells us VIP is being studied beyond immunity alone. However, the provided research bundle does not give detailed human outcome data here, so it is best to keep this as an active research area rather than a settled claim.

What This Means For Research Use

VIP is best understood as a signaling molecule with context-dependent effects. In one setting, VIP can calm inflammation, support regulatory immune pathways, and affect lung or circadian function. In another setting, the same pathway may help tumors resist immune attack.

That dual role matters when people discuss VIP as a research peptide. It is not enough to ask whether VIP is anti-inflammatory or pro-inflammatory. The better question is: in which tissue, at what dose, through which receptor, and in what disease state?

The research bundle also shows why receptor biology matters. The 2026 antagonist paper found that predicted receptor binding correlated with T-cell activation and anti-leukemia activity. That kind of finding suggests that future work may depend less on the peptide name itself and more on receptor selectivity, plasma stability, and downstream signaling.

For clinicians and researchers, the practical takeaway is that VIP is a pathway molecule. It is a target, a signal, and in some cases a risk marker. It should be studied in context, not treated as a one-size-fits-all intervention.

Administration Notes Seen In The Literature

The provided patient information document for a 5 mg injectable VIP product says it is typically administered in the morning or early afternoon. The rationale given is alignment with natural roles in circadian rhythms, energy levels, and cellular regulation. Because this is product information rather than a controlled trial, it should be treated as use guidance, not proof of outcome.

The leukemia papers in the bundle used subcutaneous administration of VIP antagonists in mice. That route and those models are relevant to antagonist research, but they should not be confused with human treatment guidance. The bundle does not provide a clinical dosing standard for human VIP use across conditions.

Open Questions In The Evidence

Several questions remain open based on the supplied research.

First, the field still needs clearer human data on when VIP improves symptoms and when it may worsen disease biology. Second, the thyroid findings suggest altered VIP signaling in autoimmune disease, but they do not show whether changing VIP meaningfully changes outcomes. Third, the cancer work is promising, but it is still mainly preclinical. Mouse survival data and in vitro T-cell findings are important, but they are not the same as clinical proof.

Finally, the receptor story is still unfolding. VIP acts through VPAC1 and VPAC2, and different tissues may respond differently. That means future work will likely focus on receptor selectivity, downstream signaling, and timing rather than on VIP alone.

FAQ

What is VIP?

VIP, or Vasoactive Intestinal Peptide, is a 28-amino-acid neuropeptide. It signals through VPAC1 and VPAC2 receptors and affects immune function, lungs, gut-related signaling, and circadian timing.

Is VIP mainly anti-inflammatory?

Many reviews describe VIP as strongly anti-inflammatory. It can reduce pro-inflammatory cytokines and support regulatory immune pathways. But the effect depends on the setting. In some cancer models, VIP signaling appears to help tumors avoid immune attack.

Why is VIP studied in leukemia?

Because blocking VIP signaling improved anti-leukemia immune responses in mouse models. A 2017 study on VIPhyb and a 2026 antagonist-screening study both found that VIP receptor blockade could enhance T-cell activity and reduce leukemia burden in preclinical models.

Does VIP have a role in circadian rhythm?

Yes. The provided materials describe VIP as involved in circadian regulation, and one patient information document says it is often given in the morning or early afternoon to fit that rhythm-related role. That timing guidance is based on product information, not a large clinical trial.

Is VIP proven to treat autoimmune disease or cancer?

No. The bundle shows strong research interest and some encouraging preclinical findings, but it does not show that VIP is a proven treatment for autoimmune disease or cancer. The evidence is still mixed and context-specific.